Jun 21, 2024, 07:58
Cancer Therapy Advisor – Results, from the STARGLO trial presented at EHA2024 by Dr Jeremy Abramson
Cancer Therapy AdvisorĀ shared a post on X:
“Glofitamab plus GemOx improved outcomes over rituximab plus GemOx in transplant-ineligible patients with relapsed/refractory DLBCL. These results, from the STARGLO trial, were presented at EHA2024 by Dr Jeremy Abramson from Mass General Cancer Center.”
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 25, 2024, 11:41
Oct 25, 2024, 09:54
Oct 25, 2024, 09:34
Oct 25, 2024, 09:05
Oct 25, 2024, 08:58
Oct 25, 2024, 08:49
Oct 25, 2024, 08:46